Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
Clinical trial NCT04895436 · RECRUITING
Trial details
- NCT number
- NCT04895436
- Sponsor
- AbbVie
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-03-28
- Primary completion
- 2026-11-01
- Enrollment
- 75
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.